Video
Dr. Dorff on greatest unmet need in metastatic castration-sensitive prostate cancer
Author(s):
Tanya Dorff, MD, explains how the next frontier in mCSPC will be the ability to select patients for treatment based more on molecular stratification and not only on disease volume or metachronous vs synchronous presentation.
Tanya Dorff, MD, describes biomarkers as the critical component to advancing the treatment paradigm for patients with metastatic castration-sensitive prostate cancer. Dorff is a medical oncologist, section chief of Genitourinary Disease Program, and associate professor in the Department of Medical Oncology & Therapeutics Research at City of Hope Comprehensive Cancer Center.
Related Videos
Related Content
